Senores Pharmaceuticals Intrinsic Value
SENORES Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹575.52 | ₹460.42 - ₹690.62 | -24.9% | EPS: ₹26.16, Sector P/E: 22x |
| Book Value Method | asset | ₹353.04 | ₹317.74 - ₹388.34 | -53.9% | Book Value/Share: ₹176.52, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹276.52 | ₹248.87 - ₹304.17 | -63.9% | Revenue/Share: ₹138.26, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹408.70 | ₹367.83 - ₹449.57 | -46.6% | EBITDA: ₹188.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹229.80 | ₹206.82 - ₹252.78 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹404.17 | ₹363.75 - ₹444.59 | -47.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹383.00 | ₹344.70 - ₹421.30 | -50.0% | ROE: 14.8%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹322.34 | ₹290.11 - ₹354.57 | -57.9% | EPS: ₹26.16, BVPS: ₹176.52 |
Want to compare with current market value? Check SENORES share price latest .
Valuation Comparison Chart
SENORES Intrinsic Value Analysis
What is the intrinsic value of SENORES?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Senores Pharmaceuticals (SENORES) is ₹383.00 (median value). With the current market price of ₹766.00, this represents a -50.0% variance from our estimated fair value.
The valuation range spans from ₹229.80 to ₹575.52, indicating ₹229.80 - ₹575.52.
Is SENORES undervalued or overvalued?
Based on our multi-method analysis, Senores Pharmaceuticals (SENORES) appears to be trading above calculated value by approximately 50.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.15 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.8% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.52x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Senores Pharmaceuticals
Additional stock information and data for SENORES
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-46 Cr | ₹-261 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-26 Cr | ₹-53 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-1 Cr | ₹-25 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-10 Cr | ₹-22 Cr | Negative Cash Flow | 3/10 |